<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21589">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769612</url>
  </required_header>
  <id_info>
    <org_study_id>S-12-14</org_study_id>
    <secondary_id>A-15174.2b</secondary_id>
    <nct_id>NCT01769612</nct_id>
  </id_info>
  <brief_title>Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia</brief_title>
  <acronym>CL Detect™</acronym>
  <official_title>Evaluation of a Rapid Diagnostic Device, CL Detect™, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InBios International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Tunisia: Ministry of Public Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the sensitivity and specificity of CL Detect, in
      subjects with suspected CL in Tunisia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Positive result for CL Detect</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Skin Diseases, Parasitic</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age and generally healthy

          -  Subject able to give written informed consent

          -  Subject has a lesion suspicious for leishmaniasis that satisfies the following
             criteria for an index lesion:

               -  less than 4 months in age

               -  primarily ulcerative, ie not purely verrucous or nodular, and does not have
                  clear clinical evidence of cellulitis

               -  in a location suitable for collecting samples by dental broach, scraping, and
                  aspiration

          -  In the opinion of the investigator, the subject is capable of understanding and
             complying with the protocol

        Exclusion Criteria:

        • Received treatment for leishmaniasis within the last 2 months prior to signing consent,
        with the exception of mercurochrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afif Ben Salah, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur of Tunis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afif Ben Salah, MD</last_name>
    <phone>011-216-71-792-429</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Primary Health Clinic</name>
      <address>
        <city>Gafsa</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afif Ben Salah, MD PhD</last_name>
      <phone>011-216-71-792-429</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Health Clinics</name>
      <address>
        <city>Sidi Bouzid</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afif Ben Salah, MD PhD</last_name>
      <phone>011-216-71-792-429</phone>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 12, 2013</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
    <mesh_term>Parasitic Diseases</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Skin Diseases, Parasitic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
